Neurocrine Biosciences, Inc. $NBIX Stock Acquired by Focus Advisor Solutions LLC

Focus Advisor Solutions LLC lifted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 67.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,124 shares of the company’s stock after buying an additional 7,690 shares during the period. Focus Advisor Solutions LLC’s holdings in Neurocrine Biosciences were worth $2,713,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. Boston Partners grew its holdings in Neurocrine Biosciences by 19.0% during the 3rd quarter. Boston Partners now owns 70,513 shares of the company’s stock worth $10,002,000 after acquiring an additional 11,245 shares during the last quarter. Meeder Asset Management Inc. boosted its position in shares of Neurocrine Biosciences by 1,513.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 468 shares of the company’s stock valued at $66,000 after purchasing an additional 439 shares in the last quarter. Impax Asset Management Group plc grew its position in shares of Neurocrine Biosciences by 8.6% during the 3rd quarter. Impax Asset Management Group plc now owns 173,727 shares of the company’s stock worth $24,641,000 after buying an additional 13,727 shares during the period. First Financial Bankshares Inc increased its stake in Neurocrine Biosciences by 1.8% in the third quarter. First Financial Bankshares Inc now owns 39,840 shares of the company’s stock valued at $5,651,000 after purchasing an additional 713 shares in the last quarter. Finally, SBI Okasan Asset Management Co.Ltd. boosted its holdings in Neurocrine Biosciences by 47.0% in the third quarter. SBI Okasan Asset Management Co.Ltd. now owns 579 shares of the company’s stock worth $80,000 after acquiring an additional 185 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

Shares of NBIX opened at $150.57 on Friday. The firm has a 50 day moving average price of $149.03 and a 200-day moving average price of $149.49. The firm has a market cap of $15.24 billion, a price-to-earnings ratio of 22.34, a PEG ratio of 0.61 and a beta of 0.36. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.29 EPS for the quarter, beating the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same quarter last year, the firm posted $2.04 earnings per share. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 8.41 earnings per share for the current year.

Insider Activity at Neurocrine Biosciences

In related news, Director George Morrow sold 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $166.37, for a total transaction of $1,197,864.00. Following the completion of the transaction, the director directly owned 10,386 shares in the company, valued at approximately $1,727,918.82. The trade was a 40.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Matt Abernethy sold 2,311 shares of the firm’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the sale, the chief financial officer directly owned 42,808 shares in the company, valued at approximately $6,729,417.60. This represents a 5.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 18,137 shares of company stock worth $2,829,332. 4.60% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on NBIX shares. Stifel Nicolaus raised their price objective on shares of Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, July 31st. TD Cowen upped their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Guggenheim lifted their price target on shares of Neurocrine Biosciences from $207.00 to $224.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Needham & Company LLC reissued a “buy” rating and issued a $204.00 price objective on shares of Neurocrine Biosciences in a report on Friday, October 16th. Finally, Wall Street Zen upgraded Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average target price of $202.59.

View Our Latest Stock Analysis on NBIX

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.

Featured Stories

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.